Advertisement GeoVax names new board member - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

GeoVax names new board member

GeoVax Labs, a biopharmaceutical company developing human vaccines for diseases caused by HIV-1 and other infectious agents, has appointed Peter Tsolinas to its board of directors.

Mr Tsolinas currently serves as chairman and CEO of TMA Group Development, a Chicago-based real estate, architectural and development firm.

Mr Tsolinas has earned a BA degree in architecture with a minor in Byzantine history from the University of Illinois.

Robert McNally, president and CEO of GeoVax, said: “We are very pleased that Mr Peter Tsolinas has agreed to join our board of directors. His substantial business experience will enhance and complement that of our current board members.”